Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) were down 49.5% during mid-day trading on Monday . The stock traded as low as $2.02 and last traded at $2.02. Approximately 400 shares changed hands during trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Performance
The company’s fifty day moving average is $2.02 and its 200-day moving average is $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Read More
- Five stocks we like better than H-CYTE
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How to Invest in Small Cap Stocks
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is a Dividend King?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
